Request Demo

Last update 21 Mar 2026

Desonide

Last update 21 Mar 2026

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

11β,21-dihydroxy-16α,17-[(1-methylethylidene)bis(oxy)]pregna-1,4-diene-3,20-dione, 11β,21-dihydroxy-16α,17-isopropylidenedioxypregna-1,4-diene-3,20-dione, 11β,21-dihydroxy-16α,17α-isopropylidenedioxypregna-1,4-diene-3,20-dione

+ [15]

Target

Action

agonists

Mechanism

GR agonists(Glucocorticoid receptor agonists)

Therapeutic Areas

Immune System DiseasesCongenital DisordersSkin and Musculoskeletal Diseases

Active Indication

DermatitisPruritusDermatitis, Atopic

Inactive Indication-

Originator Organization

Perrigo Co. Plc

Active Organization

AstraZeneca Pharmaceuticals Co. Ltd.Galderma Laboratories LP

Padagis US LLC

Inactive Organization

LEO Pharma A/S

Almirall LLCBayer Pharmaceuticals Corp.

License Organization-

Drug Highest PhaseApproved

First Approval Date

United States (04 Jan 1972),

DermatitisPruritus

Regulation-

Structure/Sequence

Molecular FormulaC24H32O6

InChIKeyWBGKWQHBNHJJPZ-LECWWXJVSA-N

CAS Registry638-94-8

Clinical Trials associated with Desonide

CTR20254761

/ RecruitingNot Applicable

地奈德软膏的一项单中心、随机、开放、单次给药、两制剂、单周期设计在中国成年健康受试者中的药效学-生物等效性（PD-BE）研究

[Translation] A single-center, randomized, open-label, single-dose, two-formulation, single-period pharmacodynamic-bioequivalence (PD-BE) study of desonide ointment in healthy adult subjects in China.

主要目的：以中国健康试验参与者为研究对象，以浙江昂利康制药股份有限公司生产并提供的地奈德软膏【规格：0.05%（15 g：7.5 mg）】为受试制剂，Perrigo New York Inc/Padagis US LLC持证的地奈德软膏【商品名：Desonide®，规格：0.05%（15 g：7.5 mg）】为参比制剂，以期达到如下目的：第一部分研究：探索参比制剂在中国健康试验参与者中的剂量持续时间-效应关系，以确定后续体内生物等效性研究中的剂量持续时间（ED50）。第二部分研究：通过比较收缩皮肤血管致使皮肤变白的作用，评价受试制剂与参比制剂是否具有生物等效性。次要目的：评价受试制剂和参比制剂在中国成年健康试验参与者中的安全性。

[Translation]

Primary Objective: This study, using healthy participants in China, employed desonide ointment (0.05% (15 g: 7.5 mg)) manufactured and supplied by Zhejiang Anglikang Pharmaceutical Co., Ltd. as the test formulation and desonide ointment (0.05% (15 g: 7.5 mg)) licensed by Perrigo New York Inc/Padagis US LLC as the reference formulation. The objectives were to achieve the following: Part 1: To explore the dose-duration-response relationship of the reference formulation in healthy participants in China to determine the dose-duration (ED50) in subsequent in vivo bioequivalence studies. Part 2: To evaluate the bioequivalence of the test and reference formulations by comparing their effects on skin whitening due to vasoconstriction. Secondary Objective: To evaluate the safety of the test and reference formulations in healthy adult participants in China.

Start Date10 Dec 2025

Sponsor / Collaborator

Zhejiang Anglikang Pharmaceutical Co. Ltd.

IRCT20240621062202N1

/ RecruitingPhase 3IIT

Comparative Study of the Effectiveness of the FraxPro Laser in Combination with Topical Desonide Compared to the Fraxpro Laser in combination with topical placebo in the Treatment of Patients with Axillary Hyperpigmentation

Start Date05 Dec 2024

Sponsor / Collaborator

Tehran University of Medical Sciences

CTR20242847

/ CompletedNot Applicable

地奈德软膏生物等效性研究与人体药代动力学对比研究

[Translation] Comparative study on bioequivalence of desonide ointment and pharmacokinetics in humans

（1）通过初步剂量持续时间-效应的探索研究测定地奈德软膏参比制剂（规格：0.05%；持证商：Padagis US LLC；商品名：Desonide®）在中国健康受试者中的剂量持续时间-效应关系，确定后续体内生物等效性试验中的剂量持续时间（ED50）和预期满足AUEC值的D2/D1最小比值的受试者比例；（2）结合初步剂量持续时间-效应探索研究结果，设计合适的研究条件，以湖南明瑞制药股份有限公司提供的地奈德软膏（规格：0.05%）为受试制剂，以Padagis US LLC持证的地奈德软膏（规格：0.05%；商品名：Desonide®）为参比制剂进行人体生物等效性试验，通过比较两制剂的药效学参数，评价两制剂的生物等效性。（3）以湖南明瑞制药股份有限公司提供的地奈德软膏（规格：0.05%）为受试制剂，以Padagis US LLC持证的地奈德软膏（规格：0.05%；商品名：Desonide®）为参比制剂，研究局部给药后受试制剂与参比制剂的体内暴露量比，从而评价受试制剂的安全性。

[Translation]

(1) The dose-duration-effect relationship of the reference preparation of desonide ointment (specification: 0.05%; licensee: Padagis US LLC; trade name: Desonide®) in Chinese healthy subjects was determined through a preliminary dose-duration-effect exploratory study, and the dose-duration (ED50) and the proportion of subjects expected to meet the minimum D2/D1 ratio of the AUEC value in the subsequent in vivo bioequivalence study were determined; (2) Based on the results of the preliminary dose-duration-effect exploratory study, appropriate research conditions were designed, and the desonide ointment (specification: 0.05%) provided by Hunan Mingrui Pharmaceutical Co., Ltd. was used as the test preparation, and the desonide ointment (specification: 0.05%; trade name: Desonide®) licensed by Padagis US LLC was used as the reference preparation for human bioequivalence testing. The bioequivalence of the two preparations was evaluated by comparing the pharmacodynamic parameters of the two preparations. (3) Desonide ointment (specification: 0.05%) provided by Hunan Mingrui Pharmaceutical Co., Ltd. was used as the test preparation, and desonide ointment (specification: 0.05%; trade name: Desonide®) certified by Padagis US LLC was used as the reference preparation. The in vivo exposure ratio of the test preparation and the reference preparation after topical administration was studied to evaluate the safety of the test preparation.

Start Date30 Aug 2024

Sponsor / Collaborator

Hunan Zhengtai Jinhu Pharmaceutical Co. Ltd.

100 Clinical Results associated with Desonide

100 Translational Medicine associated with Desonide

100 Patents (Medical) associated with Desonide

270

Literatures (Medical) associated with Desonide

01 Feb 2026·ARCHIV DER PHARMAZIE

Investigating the Telomerase Downregulatory Potential of Steroidal Drugs Following Pharmacophore‐Based Rational; Computational and In Vitro Assessments

Article

Author: Belal, Amany ; Sharaky, Marwa ; Elmaaty, Ayman Abo ; Alghamdi, Mashael A. ; Alabdali, Aya Yaseen Mahmood ; Khatib, Arwa Omar Al ; Yousef, Tarek A. ; Al‐Karmalawy, Ahmed A.

ABSTRACT:

Inhibiting telomerase could lead to telomere shortening, chromosomal instability, and eventually cell death in cancer cells. The use of steroids in cancer treatment is significant; besides, drug repurposing can be a quicker and less expensive method of drug discovery than de novo drug development. Accordingly, diverse 280 steroidal drugs—following a pharmacophore‐based rationale—were docked against telomerase receptor and compared to the co‐crystallized inhibitor (BIBR1532) as a reference standard. Additionally, a molecular dynamics simulation for 200 ns was performed to confirm the docking results. Moreover, the six steroidal drugs (Betamethasone disproportionate, Beclomethasone disproportionate, Clobetasone butyrate, Desonide, diflucortolone valerate, and Hydrocortisone butyrate) were selected for further in vitro investigation. The antitumor activities of the six steroidal drugs against H1299, HuH7, HCT116, A549, MDA‐MB‐231, MCF7, PC3, MG63, and A375 cancer cell lines, besides OEC and HSF normal cell lines, were evaluated and compared to doxorubicin (Dox) as a reference positive standard. Especially, Clobetasone butyrate represented the better cytotoxicity against seven cancer cell lines (H1299, HuH7, HCT116, MDA‐MB‐231, PC3, MG63, and A375) with IC 50 values of 12.56, 13.95, 12.00, 17.51, 11.69, 20.64, and 20.21 µg/mL, respectively. The outstanding antitumor six steroidal drugs were further investigated for their telomerase downregulatory potentials. All analogs recorded outstanding downregulatory results against telomerase, especially Clobetasone butyrate, Desonide, Diflucortolone valerate, and Hydrocortisone butyrate, where the protein expression for telomerase was downregulated up to 0.66‐, 0.76‐, 0.56‐, and 0.73‐fold change for clobetasone butyrate, desonide, diflucortolone valerate, and hydrocortisone butyrate, respectively, compared to the control.

01 Nov 2025·EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Multifunctional hydrogel for the treatment of atopic dermatitis: current advances and translational challenges

Review

Author: Wang, Miaohui ; Chen, Zhuoya ; Ma, Keqiang ; Zhou, Yibing ; Li, Jing ; Sun, Genong ; Zheng, Rui ; Zhao, Chenyu ; Zhang, Ruihan ; Song, Yuqian ; Wan, Li ; Gluchman, Martin

Atopic dermatitis (AD), the most common chronic inflammatory skin disease, is characterized by intense pruritus and varying degrees of cutaneous inflammation. Current therapeutic modalities (such as topical corticosteroids and biologics) can control symptoms in the short term, but limitations including extremely low bioavailability and significant side effects substantially restrict their clinical efficacy in AD management. Therefore, more precise and safer local management strategies for AD represent the most promising direction for future development. As a biomaterial with a three-dimensional network structure combining biomimetic properties and sustained drug delivery capability, hydrogel emerges as an optimal carrier choice. Multiple clinical trials have demonstrated that Desonide hydrogel provides substantial benefits to patients, making the design of multifunctional hydrogel dressings a research hotspot in recent years. This review first summarizes the feasible options for drug loading in hydrogels, then focuses on the advantages and disadvantages of different hydrogel types and drug delivery methods, and finally addresses the challenges and solutions for translating innovative hydrogels into clinical practice. Aimed at integrating perspectives from materials science, dermatology, and translational medicine, this review establishes a theoretical framework for the rational design of innovative hydrogels in local AD therapy.

01 Aug 2025·Journal of Cosmetic Dermatology

Axillary Hyperpigmentation Treatment: A Systematic Review of the Literature

Review

Author: Sajjadi, Sajjad ; Heidari, Sama ; Vahabi, Seyed Mohammad ; Etesami, Ifa ; Kalantari, Yasamin ; Pourgholi, Elnaz

ABSTRACT:

Introduction:

Post‐inflammatory hyperpigmentation is a common dermatologic complaint that affects different parts of the body. Axillary hyperpigmentation (AH) is a common dermatologic complaint, with no standard treatment. We aim to address the efficacy and safety of the studied treatment modalities for AH.

Methods:

A systematic search was done using “axillary” and “hyperpigmentation”‐related keywords/MeSH terms through PubMed/Medline, Scopus, Web of Science, and Embase.

Results:

Ten studies on AH were categorized into topical treatments, light/laser‐based therapies, and comparative approaches. Topical agents like niacinamide, desonide, sweet orange extract, Perilla frutescens leaf extract, Cyperus rotundus oil, glycolic acid, and novel serums demonstrated varying degrees of pigmentation reduction, with desonide and C. rotundus oil showing significant effectiveness and minimal side effects. Q‐switched Nd:YAG laser was effective across three studies. Both Q‐switched Nd:YAG laser and intense pulsed light (IPL) modalities showed significant improvement with minimal adverse events; though pain was more reported with the laser. A comparative study found IPL superior to alpha‐hydroxy acid in skin lightening and texture improvement. One study on Curcuma aeruginosa was excluded due to its primary focus on hair growth reduction rather than pigmentation.

Conclusion:

The most frequently used laser in treating AH was QS Nd‐YAG without having any severe adverse effect. Various topical treatments including Niacinamide, desonide, HQ, AHA, and a few herbal extracts were shown to be effective for AH.

News (Medical) associated with Desonide

14 Mar 2024

·www.prnewswire.com

Psoriasis in America - Insights into Psoriasis Patient Demographics, Quality of Life, Information-seeking Behaviors, HCP Engagement and Treatment Experiences

DUBLIN, March 14, 2024 /PRNewswire/ -- The "Psoriasis in America 2023: Understanding the Psoriasis Patient Experience" report has been added to ResearchAndMarkets.com's offering. Approximately 7.5 million people in the United States have psoriasis. This Psoriasis in America report provides a comprehensive look at life for those living with psoriasis. Using detailed quantitative data, it gives a full picture of the psoriasis patient experience - from symptoms to treatment to HCP relationships to quality of life - so you can make informed, strategic decisions, identify opportunities, and understand potential challenges. The report offers an in-depth look at the psoriasis patient experience. This large-scale, patient-reported data leverages vital quantitative insights essential to understanding key touchpoints in the psoriasis patient journey, including condition management, HCP engagement, quality of life, treatment experience and satisfaction, and much more. This report lifts the curtain on life with psoriasis, giving stakeholders an actionable look at the behaviors, attitudes, perceptions, needs, and experiences of people living with the condition. Data can be used to inform strategic decisions, including product communications, competitive assessments, concept development, landscape analyses, patient journey overlays, and forecasting inputs. This report also addresses important questions that stakeholders may not even know to ask while offering valuable insights into must-have patient-reported data points not available anywhere else. Add-on custom data analysis opportunities are also available for an additional cost - please see the report following purchase for more information. The analyst reaches millions of people through its portfolio of 45+ condition-specific online health communities - including PlaquePsoriasis.com - to provide information, connection, and support to patients and caregivers in the U.S. This report includes a deep-dive into: Psoriasis patient demographics Age, gender, ethnicity, marital status, children, employment status, income, location, insurance, and other health conditions Impact of psoriasis on quality of life Severity, impact on quality of life, symptoms experienced, and what patients wish others better understood Information-seeking behaviors Information sources used, plus topics of interest HCP engagement Primary HCP seen for condition, satisfaction with HCP, and discussion about brands aware of/not used Psoriasis treatment awareness and experiences Aided awareness of specific treatments, treatment experience, satisfaction with current treatments, perceived control with current treatment plan, and interest/participation in clinical trials Key questions answered in this report: To what extent do people say psoriasis impacts their overall quality of life? What's the average number of flares in the past year? What do patients wish others understood about psoriasis? What percentage of patients see a specialist for psoriasis treatment? What treatments have the highest aided brand awareness among patients? What percentage of patients use a biologic? How many patients feel their psoriasis is well-controlled on their current treatment plan? What percentage of patients are likely to switch or add new treatments in the next six months? What medications have patients discussed with their HCP? What are the top online resources people with psoriasis use to find information? What kinds of content and information do patients search for? What percentage of patients search for information on treatment options? Methodology Psoriasis in America consists of: A 20-minute online quantitative survey, covering demographics, comorbidities, quality of life/impact, HCP interactions, as well as treatment awareness, experiences, and discussions Qualitative patient insights from open-ended responses Additional details: Fielded: January 16, 2023 to April 14, 2023 Convenience sample of 490 respondents diagnosed with psoriasis Respondents are age 18+, living in the U.S., and are recruited from proprietary online health communities and recruiting partners Key Topics Covered: Respondent Demographics Research Highlights Condition Status and Quality of Life Severity and Exacerbations Symptoms Experienced Impact on Quality of Life Qualitative Patient Insights Information-Seeking Behaviors Resources Used to Manage Health Types of Content/Information Sought Treatment Awareness and Experiences Primary HCP Seen for Psoriasis Care Aided Brand Awareness of Treatments Treatment Usage Condition Control on Current Treatment and Clinical Trial Interest Treatment Discussions with HCP Appendix with All Data Charts and Distributions Brands and treatments mentioned in this report include: Topical corticosteroid (such as hydrocortisone) BRYHALIT (halobetasol propionate) lotion DesOwen (desonide) SERNIVOT (betamethasone dipropionate) SORILUXT Foam (calcipotriene) TACLONEX (calcipotriene and betamethasone) TAZORAC (tazarotene) VECTICAL (calcitriol) VTAMA (tapinarof) ZITHRANOLT-RR (anthralin) ZORYVET (roflumilast) Acitretin (SORIATANE) ARAVA (leflunomide) Azathioprine (such as IMURAN, AZASAN) Cyclosporine (such as Sandimmune, NEORAL, RESTASIS) Methotrexate (eg, Rheumatrex), also sometimes given as an injection OTEZLA (apremilast) PLAQUENIL (hydroxychloroquine) RINVOQ (upadacitinib) SOTYKTUT (deucravacitinib) Sulfasalazine (Azulfidine) XELJANZ/XELJANZ XR (tofacitinib citrate) AMJEVITAT (adalimumab-atto) Hide until launched in US AVSOLA (infliximab-axxq) CIMZIA (certolizumab) COSENTYX (secukinumab) CYLTEZO (adalimumab-adbm) Hide until launched in US ENBREL (etanercept) ERELZIT (etanercept-szzs) Hide until launched in US HULIO (adalimumab-fkjp) Hide until launched in US HUMIRA (adalimumab) HYRIMOZ (adalimumab-adaz) Hide until launched in US ILUMYAT (tildrakizumab-asmn) INFLECTRA (infliximab-dyyb) IXIFIT (infliximab-qbtx) Hide until launched in US ORENCIA (abatacept) REMICADE (infliximab) RENFLEXIST (infliximab-abda) SIMPONI (golimumab) SIMPONI ARIA (golimumab for infusion) SILIQT (brodalumab) SKYRIZI (risankizumab-rzaa) STELARA (ustekinumab) TALTZ (ixekizumab) TREMFYA (guselkumab) For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

11 May 2023

·www.drugs.com

The Most Common Allergy Medicines

THURSDAY, May 11, 2023 -- If you suffer from allergies, you know how bothersome and uncomfortable the sneezing and itchy eyes can be. These symptoms are more than irritating — they impact day-to-day activities like work, school, sports, sleeping and even eating. Not only that, but allergies can also cause more serious health problems such as asthma and even anaphylaxis, a life-threatening allergic reaction. Allergies are a common health condition affecting almost one-third of adults in the United States and just over one-quarter of children under 17, according to the U.S. Centers for Disease Control and Prevention . But there is relief at hand: Here’s what you need to know about the most common allergy medicines, the type of allergies they treat, how they work and common side effects. Antihistamines This type of allergy medicine is very effective in relieving allergy symptoms. Mayo Clinic explains this drug type works by blocking histamine, “a symptom-causing chemical released by your immune system during an allergic reaction.” Antihistamines are available as an over-the-counter medication or as a prescription allergy medicine, and they are sold in oral form, as a nasal spray or as eyedrops. This allergy medicine treats symptoms of indoor and seasonal allergies. Common side effects of antihistamines include drowsiness, dry mouth, dizziness, blurred or double vision, mucous thickening and low blood pressure. Common antihistamines include: Oral Loratadine (Alavert, Claritin) Cetirizine (Zyrtec) Diphenhydramine (Benadryl) Doxylamine (Vicks NyQuil, Tylenol Cold and Cough Nighttime) Fexofenadine (Allegra) Nasal spray Olopatadine (Patanase) Eyedrops Ketotifen (Zaditor) Leukotriene modifiers Leukotriene modifiers prevent or lessen the symptoms of allergic rhinitis (hay fever) and allergic asthma. The Cleveland Clinic explains that leukotrienes are chemicals released in the body when you come in contact with an allergen. This causes symptoms like a runny nose and coughing. Leukotriene inhibitors block the effects leukotrienes have on the body or “stop your body from producing them.” This allergy medicine treats symptoms of indoor and seasonal allergies. Leukotriene inhibitors can cause side effects such as cold or flu symptoms, headache, diarrhea, fatigue and itchy skin or rash. More serious side effects like depression, thoughts of suicide, hives, trouble breathing, vomiting and yellowing of the skin or eyes can occur. You should seek medical treatment in these cases. Common leukotriene inhibitors include: Montelukast (Singulair) Zafirlukast (Accolate) Zileuton (Zyflo) Corticosteroids Corticosteroids treat mild to severe allergy symptoms by reducing inflammation caused by your body’s reaction to an allergen. Corticosteroids are available in several forms including pills and liquids, nasal sprays, inhalers, creams and eyedrops. They treat allergic inflammation caused by indoor and seasonal allergens as well as insect stings. Severe allergic reactions are treated with oral corticosteroids, according to the Mayo Clinic. Side effects vary depending on the medication form, but can include increased blood glucose levels, high blood pressure, nosebleeds, mouth and throat irritation, and skin irritation. Common corticosteroids by form include: Pills and liquids Prednisolone (Prelone) Methylprednisolone (Medrol) Nasal sprays Budesonide (Rhinocort) Mometasone (Nasonex) Inhalers Fluticasone (Flovent) Mometasone (Asmanex Twisthaler) Creams Betamethasone (Dermabet, Diprolene) Desonide (Desonate, DesOwen) Eyedrops Fluorometholone (Flarex, FML) Loteprednol (Alrex, Lotemax) Immunotherapy Immunotherapy works by modifying the immune system and its reaction to allergens. It’s not used for immediate allergy symptom relief but is a long-term allergy treatment. Immunotherapy treatments (or allergy shots) are prescription medicines. "Allergy shots can be helpful for patients with seasonal and year-round allergies," Miranda Curtiss , an assistant professor at the University of Alabama at Birmingham School of Medicine, said in a recent article . "However, these are a long-term investment that require planning to continue therapy for three to five years for maximal benefit. Asthmatics who want to start allergy shots need to have their asthma under good control first before starting shots." With allergy shots, you are exposed to an allergen over and over until your immune system becomes desensitized and no longer reacts to the allergen, the Mayo Clinic says. This type of treatment is commonly given as allergy shots (subcutaneous immunotherapy, or SCIT), but is also available in a form given under the tongue (sublingual immunotherapy, or SLIT). With SCIT, injections are given in your doctor’s office where they can monitor for adverse reactions. Treatment starts with the “build-up phase,” which is once or twice a week, and decreases to a maintenance dose which is once every two to four weeks. Sublingual immunotherapy treatment, like subcutaneous immunotherapy, also exposes you to allergens over a period of time, with the goal of building immunity to the allergen. SLIT tablets are available by prescription and taken daily. Immunotherapy is used to treat seasonal and indoor allergies, as well as insect stings. Side effects include watery eyes, sneezing, mild asthma symptoms, a rash at the injection site, tiredness and headaches. In rare cases, life-threatening reactions such as throat swelling and difficulty breathing can occur. Regardless of the type of allergy or your symptoms, there are options for relief. Reach out to your health care provider to learn more about which remedies are best for you. Posted May 2023

Immunotherapy

02 May 2023

·www.prnewswire.com

SIFI PRESENTED NEW DATA ON XANTERDES AT ARVO 2023

CATANIA, Italy, May 2, 2023 /PRNewswire/ -- SIFI, a leading pharmaceutical company in the development of innovative solutions for the treatment of eye diseases, presented a series of scientific posters regarding preclinical and clinical research on its innovative product pipeline, during the ARVO annual meeting in New Orleans. Presentations included results from preclinical and clinical studies on XanterDES, a novel lubricating ophthalmic solution, intended to alleviate ocular discomfort in dry eye patients. "Dry eye still represents a challenge, afflicting millions of people worldwide. SIFI is fully committed to finding innovative solutions towards treating and managing this disease." stated Maria Cristina Curatolo, SIFI Innovation and Medical Science Director. "XanterDES represents an important innovation in treating dry eye due to its unique formulation and we are pleased to have presented preclinical and clinical posters on this novel eye drop." Following is a list of titles and authors: XanterDES "New eyedrops formulation based on desonide and xanthan gum: preclinical studies" (Zappulla C., La Rosa L.R., De Pasquale G., Santonocito M., Spina D., Abbate I., Curatolo M.C., Mazzone M.G., Viola S.) Presentation Number - Posterboard Number: 672 - B0343 Session Title: Dry eye XanterDES "Multicentric clinical investigation on the use of preservative-free single-dose ophthalmic solution based on 0.2% xanthan gum and 0.025% desonide sodium phosphate in the treatment of ocular discomfort in patients with dry eye" (Giannaccare G., Gagliano C., Civiale C., Aragona P.) Presentation Number - Posterboard Number: 3957 - B0274 Session Title: Dry eye (clinical) XanterDES "Efficacy and Safety of a Novel Ophthalmic Solution Containing 0.2% Xanthan Gum and 0.025% Desonide Sodium Phosphate for the Treatment of Dry Eye Disease" (Rossi C., Bifezzi L., Carnovale Scalzo G., Scorcia V., Giannaccare G.) Session Title: Dry eye (clinical) XanterDES is a lubricating ophthalmic solution, intended to relieve discomfort and eye irritation due to environmental factors such as dust, heat, smoke, wind, air conditioning and allergens and is part of SIFI's well-known dry eye disease therapeutic portfolio. XanterDES is already available in Italy and in Romania and will be soon available in other markets as well. SIFI is a leading international ophthalmic company, headquartered in Italy, focusing on eye care since 1935. SIFI develops, manufactures, and markets innovative therapeutic solutions for patients with ophthalmic conditions. SIFI is fully committed through its R&D to improving the quality of life of patients, exporting treatments to more than 40 countries worldwide with a direct presence in Italy, Spain, France, Romania, Mexico, and Turkey. Contact: [email protected], +39 3336999669 SOURCE SIFI S.p.A.

100 Deals associated with Desonide

External Link

KEGG	Wiki	ATC	Drug Bank
D03696	Desonide	S01BA11 D07AB08	DB01260

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Dermatitis, Atopic	United States	Padagis US LLC	01 Nov 1974
Dermatitis	United States	Padagis US LLC	04 Jan 1972
Pruritus	United States	Padagis US LLC	04 Jan 1972

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00690833 (CTgov)	Phase 4	Dermatitis, Atopic	41	desonide	mpmyqktcvz(gikqsticba) = reuzcthakt kfywcnsxsz (agreiwxqul, 0.5) View more	-	28 Mar 2017

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis